A Study of Residual Curarization Incidence in China

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University First Hospital
• Collaborators: Central South University; China Medical University Hospital; Chinese PLA General Hospital; Eastern Hepatobiliary Surgery Hospital; First Affiliated Hospital of Xinjiang Medical University; First Affiliated Hospital of Zhejiang University; First Affiliated Hospital, Sun Yat-Sen University; Hebei Medical University Fourth Hospital; Peking Union Medical College Hospital; RenJi Hospital; Ruijin Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Zhongshan Hospital; The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Zhengzhou University; The First Teaching Hospital of Xinjiang Medical University; Tianjin Medical University General Hospital; Tongji Hospital; West China Hospital; Wuhan Union Hospital, China; Xiangya Hospital of Central South University; Zhujiang Hospital
• Treatments: Atracurium; Bromides; Cisatracurium; Rocuronium; Vecuronium Bromide

Criteria

Inclusion Criteria:

• Aged 18 or older

• Nondepolarized NMBA will be given during surgery and tracheal extubation will be performed after surgery

• Willing to comply with all study procedures and provide signed and dated informed consent

Exclusion Criteria:

• Allergic reaction to gel electrode

• Neuromuscular disorders and hepatic or renal dysfunction

• Scheduled to receive mechanical ventilation therapy

• Involved in other clinical trials

• Body position and surgical procedure affecting TOF-Watch SX normal function